The round was led by new investor Gilde Healthcare with participation from existing investors Versant Ventures and U.S. Venture Partners. In conjunction with the funding, Geoff Pardo of Gilde Healthcare will join Inari’s Board of Directors.
The company will use the funds to commercialize its catheter-based technologies for the treatment of venous thromboembolism (“VTE”), and continue to advance clinical and technology development programs.
Led by Bill Hoffman, President and Chief Executive Officer, Inari is dedicated to the development of innovative catheter-based technologies for the treatment of venous thromboembolism (“VTE”). To date, the company has developed the FlowTriever and ClotTriever Systems, both of which are designed to enable the safe removal of large clot volumes from big vessels without the use of thrombolytic drugs.
Both Systems are 510(k) cleared by the U.S. FDA for thrombectomy in the peripheral vessels and have also received the CE mark.
FinSMEs
29/03/2018